P. Bedard and F. Cardoso, Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?, Nature Reviews Clinical Oncology, vol.116, issue.5, pp.272-279, 2011.
DOI : 10.1038/nrclinonc.2011.19

T. Sørlie, C. Perou, R. Tibshirani, T. Aas, and S. Geisler, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, p.11553815, 2001.
DOI : 10.1073/pnas.191367098

W. Foulkes, J. Reis-filho, and S. Narod, Tumor size and survival in breast cancer???a reappraisal, Nature Reviews Clinical Oncology, vol.27, issue.6, pp.348-353, 2010.
DOI : 10.1038/nrclinonc.2010.39

R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, and M. Cristofanilli, Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy, Clinical Cancer Research, vol.11, issue.16, pp.5678-5685, 2005.
DOI : 10.1158/1078-0432.CCR-04-2421

S. Banerji, K. Cibulskis, C. Rangel-escareno, K. Brown, and S. Carter, Sequence analysis of mutations and translocations across breast cancer subtypes, Nature, vol.274, issue.7403, pp.405-409, 2012.
DOI : 10.1038/nature11154

P. Stephens, P. Tarpey, H. Davies, V. Loo, P. Greenman et al., The landscape of cancer genes and mutational processes in breast cancer, Nature, vol.135, pp.400-404, 2012.
DOI : 10.1038/nature11017

S. Chin, Y. Wang, N. Thorne, A. Teschendorff, and S. Pinder, Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers, Oncogene, vol.23, issue.13, p.17001317, 2007.
DOI : 10.1038/sj.onc.1209985

M. Guedj, L. Marisa, A. De-reynies, B. Orsetti, and R. Schiappa, A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2011.
DOI : 10.1038/nature09515
URL : https://hal.archives-ouvertes.fr/inserm-00611752

I. Ellis, M. Galea, N. Broughton, A. Locker, and R. Blamey, Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up, Histopathology, vol.63, issue.6, pp.479-489, 1992.
DOI : 10.1111/j.1365-2559.1992.tb01032.x

E. Luporsi, F. André, F. Spyratos, P. Martin, and J. Jacquemier, Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Research and Treatment, vol.63, issue.Suppl, pp.895-915, 2011.
DOI : 10.1007/s10549-011-1837-z

C. Sotiriou, P. Wirapati, S. Loi, A. Harris, and S. Fox, Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis, JNCI Journal of the National Cancer Institute, vol.98, issue.4, pp.262-272, 2006.
DOI : 10.1093/jnci/djj052

J. Cuzick, M. Dowsett, S. Pineda, C. Wale, and J. Salter, Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer, Journal of Clinical Oncology, vol.29, issue.32, pp.4273-4278, 2011.
DOI : 10.1200/JCO.2010.31.2835

K. Chin, S. Devries, J. Fridlyand, P. Spellman, and R. Roydasgupta, Genomic and transcriptional aberrations linked to breast cancer pathophysiologies, Cancer Cell, vol.10, issue.6, pp.529-541, 2006.
DOI : 10.1016/j.ccr.2006.10.009

C. Curtis, S. Shah, S. Chin, G. Turashvili, and O. Rueda, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.452, pp.346-352, 2012.
DOI : 10.1038/nature10983

N. Birkbak, A. Eklund, Q. Li, S. Mcclelland, and D. Endesfelder, Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer, Cancer Research, vol.71, issue.10, pp.3447-3452, 2011.
DOI : 10.1158/0008-5472.CAN-10-3667

S. Carter, A. Eklund, I. Kohane, L. Harris, and Z. Szallasi, A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers, Nature Genetics, vol.1, issue.9, p.16921376, 2006.
DOI : 10.1038/nrc1802

F. Chibon, P. Lagarde, S. Salas, G. Pérot, and V. Brouste, Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity, Nature Medicine, vol.99, issue.7, pp.781-787, 2010.
DOI : 10.1038/nm.2174

J. Habermann, J. Doering, S. Hautaniemi, U. Roblick, and N. Bündgen, The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome, International Journal of Cancer, vol.21, issue.7, pp.1552-1564, 2009.
DOI : 10.1002/ijc.24017

R. Roylance, D. Endesfelder, P. Gorman, R. Burrell, and J. Sander, Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.20, issue.10, pp.2183-2194, 2011.
DOI : 10.1158/1055-9965.EPI-11-0343

E. Gravier, G. Pierron, A. Vincent-salomon, N. Gruel, and V. Raynal, A prognostic DNA signature for T1T2 node-negative breast cancer patients, Genes, Chromosomes and Cancer, vol.69, issue.Suppl 6, p.20842727, 2010.
DOI : 10.1002/gcc.20820

H. Russnes, H. Vollan, O. Lingjaerde, A. Krasnitz, and P. Lundin, Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients, Science Translational Medicine, vol.2, issue.38, pp.38-47, 2010.
DOI : 10.1126/scitranslmed.3000611

M. Smid, M. Hoes, A. Sieuwerts, S. Sleijfer, and Y. Zhang, Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes, Breast Cancer Research and Treatment, vol.107, issue.2, pp.23-30, 2010.
DOI : 10.1007/s10549-010-1026-5
URL : https://hal.archives-ouvertes.fr/hal-00615363

R. Blamey, B. Hornmark-stenstam, G. Ball, M. Blichert-toft, and L. Cataliotti, ONCOPOOL ??? A European database for 16,944 cases of breast cancer, European Journal of Cancer, vol.46, issue.1, pp.56-71, 2009.
DOI : 10.1016/j.ejca.2009.09.009

C. Elston and I. Ellis, pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, pp.403-410, 1991.
DOI : 10.1016/0277-5379(88)90171-X

A. Vincent-salomon, C. Lucchesi, N. Gruel, V. Raynal, and G. Pierron, Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast, Clinical Cancer Research, vol.14, issue.7, pp.1956-1965, 2008.
DOI : 10.1158/1078-0432.CCR-07-1465

F. Reyal, M. Bollet, M. Caly, D. Gentien, and S. Carpentier, Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma, PLOS ONE, vol.7, p.22529987, 2012.

M. Dowsett, T. Nielsen, A. Hern, R. Bartlett, J. Coombes et al., Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI Journal of the National Cancer Institute, vol.103, issue.22, pp.1656-1664, 2011.
DOI : 10.1093/jnci/djr393

A. Goldhirsch, W. Wood, A. Coates, R. Gelber, and B. Thürlimann, Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology, vol.22, issue.8, pp.1736-1747, 2011.
DOI : 10.1093/annonc/mdr304

A. Prat, M. Cheang, M. Martín, J. Parker, and E. Carrasco, Prognostic Significance of Progesterone Receptor???Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer, Journal of Clinical Oncology, vol.31, issue.2, p.23233704, 2013.
DOI : 10.1200/JCO.2012.43.4134

A. Vincent-salomon, V. Raynal, C. Lucchesi, N. Gruel, and O. Delattre, ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 802; author reply: 802. doi:10, pp.708-810, 1038.

G. Rigaill, runed dynamic programming for optimal multiple change-point detection, 2010.

N. Zhang and D. Siegmund, A Modified Bayes Information Criterion with Applications to the Analysis of Comparative Genomic Hybridization Data, Biometrics, vol.6, issue.1, pp.22-32, 2007.
DOI : 10.1111/j.1541-0420.2006.00662.x

F. Picard, E. Lebarbier, M. Hoebeke, G. Rigaill, and B. Thiam, Joint segmentation, calling, and normalization of multiple CGH profiles, Biostatistics, vol.12, issue.3, 2011.
DOI : 10.1093/biostatistics/kxq076
URL : https://hal.archives-ouvertes.fr/hal-01019859

M. Piccart-gebhart and C. Sotiriou, Adjuvant chemotherapy yes or no? Prognostic markers in early breast cancer, Annals of Oncology, vol.18, issue.Supplement 12, 2007.
DOI : 10.1093/annonc/mdm532

R. Stuart-harris, C. Caldas, S. Pinder, and P. Pharoah, Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, 2008.
DOI : 10.1016/j.breast.2008.02.002

S. Paik, S. Shak, G. Tang, C. Kim, and J. Baker, A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer, New England Journal of Medicine, vol.351, issue.27, pp.2817-282610, 2004.
DOI : 10.1056/NEJMoa041588

M. Ignatiadis and C. Sotiriou, Breast cancer: Should we assess HER2 status by Oncotype DX???, Nature Reviews Clinical Oncology, vol.360, issue.1, pp.12-14, 2011.
DOI : 10.1038/nrclinonc.2011.188

D. Dabbs, M. Klein, S. Mohsin, R. Tubbs, and Y. Shuai, DX Test: An Independent Quality Assurance Study, Journal of Clinical Oncology, vol.29, issue.32, pp.4279-4285, 2011.
DOI : 10.1200/JCO.2011.34.7963

S. Barton, L. Zabaglo, A. Hern, R. Turner, N. Ferguson et al., Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer, British Journal of Cancer, vol.19, issue.11, p.22531639, 2012.
DOI : 10.2217/14796694.4.5.603

G. Tang, J. Cuzick, J. Costantino, M. Dowsett, and J. Forbes, Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor???Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors, Journal of Clinical Oncology, vol.29, issue.33, pp.4365-4372, 2011.
DOI : 10.1200/JCO.2011.35.3714

M. Arnedos, V. Scott, J. B. , D. L. Cruz, J. Commo et al., Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer, European Journal of Cancer, vol.48, issue.15, p.22840369, 2012.
DOI : 10.1016/j.ejca.2012.06.014

O. Krijgsman, D. Israeli, J. Haan, H. Van-essen, and S. Smeets, CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material, Genes, Chromosomes and Cancer, vol.38, issue.105, pp.344-352, 2011.
DOI : 10.1002/gcc.21920